期刊文献+

MTT比色分析法检测卵巢癌药物敏感性 被引量:3

Detection of chemosensitivity of ovarian cancer with MTT colorimetric assay
下载PDF
导出
摘要 目的探讨四氮唑蓝比色分析法(MTT法)用于指导临床个体化化疗药物选择的实用性,为卵巢癌临床化疗用药提供参考。方法采用常用的12种化疗药物对65例卵巢癌进行MTT法药物敏感试验。结果不同类型的卵巢癌及同一类型的不同个体对化疗药物的敏感性差异较大。卵巢癌对紫杉醇、表阿霉素、卡铂和顺铂中度敏感,平均抑制率分别为(67.3±4.6)%、(54.5±4.8)%、(52.0±4.3)%和(50.8±4.5)%;对鬼臼乙叉甙、烃基喜树碱和长春地新低度敏感,平均抑制率分别为(39.6±3.8)%、(39.3±4.3)%和(30.7±2.6)%;而对丝裂霉素C、噻替哌、5氟尿嘧啶、长春新碱和氨甲喋呤则耐药,平均抑制率均小于30%。结论卵巢癌化疗敏感性个体差异较大。MTT法是一种简便而快速的肿瘤体外药物敏感实验方法,可为卵巢癌临床个体化化疗方案的选择提供客观依据。 Objective: To assess the practicability of in vitro chemosensitivity testing in ovarian cancer using MTT colorimetric assay, and to help clinical doctors choose more effective chemotherapeutic agents. Methods:Chemosensitivity of 65 ovarian cancer samples to 12 drugs were detected in vitro with MTT assay. Results:There was a great difference in sensitivity to anticancer agents between different kinds of ovarian cancer and between patients with same kind of ovarian cancer. Ovarian cancer cells had great sensitivity to Paclitaxel,Epirubicin,carboplatin, and Cisplatin at (67.3±4.6)%,(54.5±4.8)%,(52.0±4.3)%,and (50.8±4.5)% of average inhibition rate respectively. Low sensitivity was shown to Etoposide,Hydrocarbonyl Camptothecin, and Vindesine at (39.6±3.8)%,(39.3±4.3)%,and (30.7±2.6)% of average inhibition rate respectively. There was drug resistance to mitomycin C,Thiotepa,5-Fluorouracil,Vincristine, and Methotrexate at average inhibition rate less than 30%. Conclusion:There was a great difference in sensitivity to anticancer agents between different patients with ovarian cancer. The MTT assay is a simple technique, rapid for testing of chemosensitivity, and helpful to compose individual chemotherapeutic scheme for patients.
出处 《中国医科大学学报》 CAS CSCD 北大核心 2004年第6期540-543,共4页 Journal of China Medical University
关键词 卵巢肿瘤 化疗药物敏感试验 四氮唑蓝比色分析法 ovarian neoplasm chemosensitivity testing MTT colorimetric assay
  • 相关文献

参考文献7

  • 1Witters LM,Santala SM, Engle L, et al. Decreased response to Paclitaxel versus docetaxel in her-2/neu transfected human breast cancer cells[J]. Am J Clin Oncol, 2003,26(1) :50 -54.
  • 2Cruz MT, Duarte CB, Goncalo M,et al. The sensitizer 2,4-Dinitrofluorobenzene activates caspase-3 and induces cell death in a skin dendritic cell line[J]. Int J Toxicol,2003,22(1) :43 -48.
  • 3Mckeague AL, Wilson DJ, Nelson. Staurosporine-induced apoptosis and hydrogen peroxide-induced necrosis in two human breast cell lines[J]. Br J Cancer, 2003,88(1): 125 - 131.
  • 4Taylor CG, Sargent JM, Elgie AW, et al. Chemosensitivity testing predicts survival in ovarian cancer [J]. Eur J Gynaecol Oncol,2001,22(4) :278 -282.
  • 5Taylor CG, Sargent JM, Elgie AW, et al. The clinical relevance of chemosensitivity testing in ovarian cancer[J]. Cancer Detection and Prevention, 1998,22 (4) :305 - 312.
  • 6Koshiyama M, Fujii H, Kinezaki M, et al. lmmunohistochemical expression of topoisomerase lalpha ( Topo lalpha) and multidrug resistance-associated protein (MRP), plus chemosensitivity testing,as chemotherapeutic indices of ovarian and endometrial carcinom
  • 7Coley HM ,Sargent JM, Williamson CJ ,et al. Assessment of the classical MDR phenotype in epithelial ovarian carcinoma using primary cultures: a feasibility study [J]. A nticancer Res,2002,22 (1) :69 -74.

共引文献1

同被引文献35

  • 1李洪君,吴令英,章文华,李晓光,张蓉,刘玉英,赵清正.体外MTT法预测卵巢上皮癌化疗药敏性与体内疗效相关性的评估[J].中国肿瘤临床,2006,33(9):521-523. 被引量:4
  • 2FRESNO VARA JF,CASADO E ,DE CASTRO J,et al. PI3K/Akt signaling pathway and cancer [ J ]. Cancer Treat Rev, 2004,30 (2) : 193-204.
  • 3OSAKI M,OSHIMURA M,ITO H. PI3K-Akt pathway :its functions and alterations in human cancer [J]. Apoptosis,2004,9 (6):667- 676.
  • 4SUN M ,WANG G ,PACIGA JE ,et al. AKT1/PKB alpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells [J]. Am J Pathol,2001,159(2) :431-437.
  • 5MALIK SN , BRATTAIN M , GHOSH PM , et al. Immunohistochemi- cal demonstration of phosphor-akt in high gleason grade prostate cancer[J]. Clin Cancer Res,2002,8(4): 1168-1171.
  • 6HU L , HOFMANN J , LU Y, et al. Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models[J]. Cancer Res,2002,62(4): 1087-1092.
  • 7YUAN ZQ,SUN M ,FELDMAN RI ,et al. Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3- OH kinase/Akt pathway in human ovarian cancer[J].Oncogene , 2000,19(19) :2324-2330.
  • 8TAYLOR CG ,SARGENT JM ,Elgie AW ,et al. The clinical relevance of chemosensitivity testing in ovarian cancer [J].Cancer Detection and Prevention, 1998,22 (4) : 305-312.
  • 9TAYLOR CG, SARGENT JM , ELGIE AW , et al. Chemosensitivity testing predicts survival in ovarian cancer [J]. Eur J Gynaecol Oncol, 2001,22(4) : 278-282.
  • 10KOSHIYAMA M ,FUJII H ,KINEZAKI M ,et al. Immunohistochemical expression of topoisomerase Ⅱ alpha (Topo Ⅱ alpha) and muhidrug resistance-associated protein (MRP), plus chemosensitivity testing, as chemotherapeutic indices of ovarian and endometrial carcinomas [ J ]. Anticancer Res, 2001,21 (4B) : 2925-2932.

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部